Myriad Genetics (MYGN) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.26, $0.02 better than the analyst estimate of $0.24. Revenue for the quarter came in at $196.5 million versus the consensus estimate of $189.72 million.
GUIDANCE:
Myriad Genetics sees Q3 2017 EPS of $0.23-$0.25, versus the consensus of $0.25.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Uber Q3 profit, revenue beat estimates as gross bookings jump 20%
- CS Disco, Inc (LAW) Misses Q3 EPS by 6c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
